In the version of this paper originally published, the 'phase' entry for PBT2 in Table 1 was inadvertently labeled as 'Discontinued'. It has now been corrected to phase 2. Additionally, at the time of this corrigendum, the U.S. Food and Drug Administration status of AZD3293 has changed to phase 2/3 on Alzforum's database of amyloid-related therapeutics, and Epothilone D has been discontinued. Lastly, BIIB037 (Aducanumab) has been announced to be proceeding to phase 3 trials. The respective table entries have been amended to reflect these changes in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nchembio.1663
Rights and permissions
About this article
Cite this article
Narayan, P., Ehsani, S. & Lindquist, S. Correction: Corrigendum: Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol 11, 172 (2015). https://doi.org/10.1038/nchembio0215-172c
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio0215-172c
